Member Info for DinoMustafic

How can they raise dividend, with reporting net loss, and what will happen with the suit against them by the GSK and Pfizer's company... Is the suit with a good foundation? Is this the product they got FDA's OK for? Is that, I mean, the one they're being sued over? http://www.pharmaceuticaldaily.com/viiv-healthcare-sues-gilead-over-hiv-drug-containing-bictegravir-patent- infringmenet-gilead-increases-dividend-10-after-posting-net-loss-in-q4-2017/

Arix Biosciences http://bit.ly/2tk0Yxn

“LogicBio has huge potential and, alongside its excellent team and investors, we look forward to supporting the company to achieve continued success in this area,” CEO said.

Swissmedic to review Takeda, TiGenix’s Chron’s disease treatment Cx601 http://bit.ly/2tng6Yk

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics http://bit.ly/2qRKrPt

Oxford BioDynamics said it signed a development agreement with two pharmaceutical companies http://bit.ly/2qR9wZr

AstraZeneca enters in agreement with Recordati S.p.A for certain commercial rights http://bit.ly/2q2KY2r

Arix Bioscience on Friday said that its new business group, Iterum, has raised $65 million by closing a Series B investment round. http://bit.ly/2qDoWAg

Hikma's US subsidiary has launched in USA the generic equivalent to Edecrin (ethacrynic acid) for the treatment of edema. http://bit.ly/2pT2h1N

Novartis’ has posted a first quarter net income down 15% citing a net charge related to the discontinuation of RLX030 ($-0.2 billion), as well as the decline in core operating income. http://bit.ly/2q9bIKe

Kevzara in the European Union in the coming months. http://bit.ly/2okvWEu

http://bit.ly/2ooD559

Hikma finds tuned in for Jazz (pharmaceuticals). It'll pay royalties, but keep some percentage... http://bit.ly/2oDdaI1

Sanofi welcomes new Genzyme's EVP http://bit.ly/2oCA7uv

Abzena looks to boost growth. http://bit.ly/2nCOc6B

Bioventix's increases profit in second half of 2016 http://bit.ly/2n8DtSc

PureTech Health has allocated approximately $15 million in several tranches to the development of the programme as it progresses and continues to be de-risked. http://bit.ly/2nY94qb

2017 has started well with the launch in the Middle East of CSD500, our novel erectogenic condom http://bit.ly/2nfEDOe

Novartis’s acute heart failure drug disappoints in phase three. So a lot of money gone pretty much nowhere. http://bit.ly/2o3nKUh

"AstraZeneca’s diabetes drug reduces the risk of heart failure". Things like this are always good. http://bit.ly/2nqWPoK